http://www.modernmedicine.com/modernmedicine/Retinal+Disease/Article/list/46408 Visit ModernMedicine.com, a medical resource for physicians, to find coding and formulary tools, free CME, patient education, medical news and articles, and more. 2009-11-21T20:02:51Z http://www.modernmedicine.com/modernmedicine/Retinal+Disease/Cataract-Surgery-Unlikely-to-Affect-the-Progressio/ArticleNewsFeed/Article/detail/642025?contextCategoryId=46408&ref=25 In patients with non-neovascular age-related macular degeneration (AMD), cataract surgery is not associated with an increased risk of AMD progression. In addition, dietary fats may have differential effects on the risk of AMD, according to two studies in the November issue of the Archives of Ophthalmology. 2009-11-16T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/472009/642025/SS36006.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/472009/642025null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Cataract-Surgery-May-Benefit-Macular-Degeneration/ArticleNewsFeed/Article/detail/640328?contextCategoryId=46408&ref=25 Individuals with varying degrees of age-related macular degeneration may benefit in terms of visual acuity from cataract surgery, according to the Age-Related Eye Disease Study published in the November issue of Ophthalmology. 2009-11-09T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/462009/640328/eyechart.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/462009/640328null XML http://www.modernmedicine.com/modernmedicine/ModernMedicine+Now/Lumenis-unveils-retinal-laser-delivery-technology/ArticleStandard/Article/detail/639042?contextCategoryId=46408&ref=25 Lumenis Ltd. introduced an ophthalmic laser delivery technology and slit lamp biomicroscope system (InSight) at the recent annual meeting of the American Academy of Ophthalmology. 2009-11-04T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/452009/639042null HTML http://www.modernmedicine.com/modernmedicine/ModernMedicine+Now/Notal-Vision-sells-Foresee-PHP-business-to-Reicher/ArticleStandard/Article/detail/638996?contextCategoryId=46408&ref=25 Notal Vision has sold its clinic-based preferential hyperacuity perimeter (Foresee PHP) business to Reichert Ophthalmic Instruments. 2009-11-04T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/452009/638996null HTML http://www.modernmedicine.com/modernmedicine/ModernMedicine+Now/Ellex-unveils-new-generation-of-diagnostic-ultraso/ArticleStandard/Article/detail/639015?contextCategoryId=46408&ref=25 Ellex Medical Lasers Ltd. unveiled the latest version of its diagnostic ultrasound system (Eye Cubed) at the recent annual meeting of the American Academy of Ophthalmology. 2009-11-04T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/452009/639015null HTML http://www.modernmedicine.com/modernmedicine/ModernMedicine+Now/MacuSight-gets-FDA-fast-track-designation-for-DME-/ArticleStandard/Article/detail/639006?contextCategoryId=46408&ref=25 MacuSight has received fast-track designation from the FDA for its proprietary ocular sirolimus (Perceiva) product for the treatment of diabetic macular edema. 2009-11-04T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/452009/639006null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Early-AMD-May-Increase-Heart-Disease-Risk-in-Older/ArticleNewsFeed/Article/detail/633746?contextCategoryId=46408&ref=25 Older adults with early age-related macular degeneration may be at higher risk of coronary heart disease, according to the Cardiovascular Health Study published in the October issue of Ophthalmology. 2009-10-13T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/422009/633746/eyechart_59082.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/422009/633746null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/AMD-Alliance-International-organizes-video-contest/ArticleStandard/Article/detail/631188?contextCategoryId=46408&ref=25 AMD Alliance International is hosting a video contest to raise awareness for age-related macular degeneration (AMD). Individuals are invited to create and submit videos of no longer than 3 minutes that will communicate in the most creative and visually interesting ways the impact of AMD. 2009-10-02T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/402009/631188null HTML http://www.modernmedicine.com/modernmedicine/Industry+News/FDA-clears-Topcon-digital-fundus-camera/ArticleStandard/Article/detail/631229?contextCategoryId=46408&ref=25 The FDA has granted 510(k) clearance to a new digital fundus camera (TRC-NW7SF Mark II, Topcon Medical Systems), according to its manufacturer. 2009-10-02T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/412009/631229null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diabetic-macular-edema-responds-to-ranibizumab-in-/ArticleStandard/Article/detail/627818?contextCategoryId=46408&ref=25 Diabetic macular edema responds to treatment with ranibizumab (Lucentis, Genentech), according to results of the RESOLVE study. The patient responses to the drug in the changes in the visual acuity and central macular thickness were significantly better in the groups treated with two concentrations of ranibizumab compared with the sham-treated group. 2009-09-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/382009/627818null XML http://www.modernmedicine.com/modernmedicine/Industry+News/Art-exhibit-focuses-on-macular-degeneration/ArticleStandard/Article/detail/623206?contextCategoryId=46408&ref=25 To mark the global observance of AMD [age-related macular degeneration] Week, Lighthouse International and AMD Alliance International (AMDAI) will host an exhibit of the works of London-based portrait artist Adam Hahn, whose paintings illustrate how patients with AMD see the world. 2009-09-02T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/362009/623206null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Anti-vascular-endothelial-growth-factor-monotherap/ArticleStandard/Article/detail/627658?contextCategoryId=46408&ref=25 Anti-vascular endothelial growth factor monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement or stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections. 2009-09-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/382009/627658null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Lowering-levels-of-arginase-may-halt-progression-o/ArticleStandard/Article/detail/621078?contextCategoryId=46408&ref=25 High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy, according to researchers at the Medical College of Georgia (MCG) School of Medicine. 2009-08-24T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/352009/621078null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Anti-VEGF-found-to-improve-vision-when-used-for-pa/ArticleStandard/Article/detail/617166?contextCategoryId=46408&ref=25 In a study conducted by the Pan-American Collaborative Retina Study Group, treatment of diffuse diabetic macular edema with bevacizumab (Avastin, Genentech) was shown to improve vision. 2009-08-06T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/322009/617166null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/ANV-therapy-system-receives-CE-mark-approval/ArticleStandard/Article/detail/616506?contextCategoryId=46408&ref=25 NeoVista Inc. received approval from BSI Product Services to apply the CE mark to its anti-neovascular (ANV) therapy system (Vidion) to treat wet age-related macular degeneration (AMD), the company announced. 2009-08-05T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/322009/616506null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/E10030-ranibizumab-have-biologic-activity-against-/ArticleStandard/Article/detail/617071?contextCategoryId=46408&ref=25 In a phase I study, E10030 (Ophthotech) combined with ranibizumab (Lucentis, Genentech) in patients with subfoveal neovascular age-related macular degeneration was well tolerated and seemed to have biologic activity against choroidal neovascularization, according to one ophthalmologist. 2009-08-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/322009/617071null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/When-treating-diabetic-macular-edema-focalgrid-pho/ArticleStandard/Article/detail/617066?contextCategoryId=46408&ref=25 Intravitreal triamcinolone (IVTA) for treating diabetic macular edema (DME) does not seem to be beneficial over the long term compared with focal/grid photocoagulation, and treatment with IVTA results in a higher chance of developing a cataract compared with treatment with the laser, according to a 3-year comparison study. Focal/grid photocoagulation, therefore, remains the most effective treatment for DME, according to one ophthalmologist. 2009-08-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/322009/617066null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Oral-fenretinide-may-slow-halt-geographic-atrophy-/ArticleStandard/Article/detail/617068?contextCategoryId=46408&ref=25 Oral fenretinide given once daily may slow the progression of geographic atrophy in patients with age-related macular degeneration, according to an interim analysis. 2009-08-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/322009/617068null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Genentech-reports-positive-results-in-phase-III-st/ArticleStandard/Article/detail/610825?contextCategoryId=46408&ref=25 Ranibizumab (Lucentis, Genentech) improved vision in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) when compared with sham injections, according to results of a phase III study announced by Genentech. 2009-07-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/292009/610825null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dexamethasone-implant-a-first-for-macular-edema-af/ArticleStandard/Article/detail/610908?contextCategoryId=46408&ref=25 The recently approved dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion first delivers the drug in a high dose and then in a lower, sustained dose. This delivery may allow better control of the disease while minimizing corticosteroid side effects. The drug also reduces inflammation, which may play an important role in RVO. 2009-07-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/292009/610908null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Approach-to-wet-age-related-macular-degeneration-v/ArticleStandard/Article/detail/606442?contextCategoryId=46408&ref=25 In part one of a two-part series, retinal specialist discuss various dosing strategies for ranibizumab in the treatment of patients with age-related macular degeneration as well as the use of diagnostic tools. 2009-07-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/262009/606442null XML http://www.modernmedicine.com/modernmedicine/Retina/FDA-approves-implant-for-macular-edema-associated-/ArticleStandard/Article/detail/606846?contextCategoryId=46408&ref=25 The FDA has approved dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion. 2009-07-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/262009/606846null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/DHA-EPA-Low-Glycemic-Index-Help-in-Macular-Degener/ArticleNewsFeed/Article/detail/606675?contextCategoryId=46408&ref=25 Diets that contain more omega-3 fatty acids and have a lower glycemic index may help prevent progression to advanced age-related macular degeneration, according to research published online June 12 in the British Journal of Ophthalmology. 2009-06-25T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/262009/606675/eye_40179.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/262009/606675null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Omega-3-fatty-acids-may-prevent-progression-of-AMD/ArticleStandard/Article/detail/605748?contextCategoryId=46408&ref=25 Omega-3 fatty acids found in fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD). 2009-06-22T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/262009/605748null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Dexamethasone-receives-FDA-approval-for-the-treatm/ArticleStandard/Article/detail/604831?contextCategoryId=46408&ref=25 Dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan), indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), has been approved by the FDA. Retinal vein occlusion including BRVO and CRVO is the second most common retinal vascular disease after diabetic retinopathy. 2009-06-18T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/252009/604831null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/CCR3-linked-to-neovascular-AMD-according-to-resear/ArticleStandard/Article/detail/604488?contextCategoryId=46408&ref=25 Researchers identified a biological marker, CCR3, which is linked to the development and progression of neovascular age-related macular degeneration (AMD). 2009-06-17T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/252009/604488null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/New-Protein-Target-Key-to-Prevent-Macular-Degenera/ArticleNewsFeed/Article/detail/604536?contextCategoryId=46408&ref=25 Blocking the activity of the protein eosinophil/mast cell chemokine receptor can reduce the abnormal blood vessel growth that leads to age-related macular degeneration, a leading cause of blindness worldwide, according to a study published online June 14 in Nature. 2009-06-17T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/252009/604536/33101.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/252009/604536null XML http://www.modernmedicine.com/modernmedicine/Industry+News/OCT-system-with-RNFL-and-macular-databases-approve/ArticleStandard/Article/detail/602910?contextCategoryId=46408&ref=25 A new optical coherence tomography (OCT) software application (Cirrus [high-definition] HD-OCT, Carl Zeiss Meditec) has been cleared by the FDA for commercial distribution. 2009-06-11T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/242009/602910null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diet-Associated-With-Slower-Eye-Degeneration/ArticleNewsFeed/Article/detail/602684?contextCategoryId=46408&ref=25 Patients with early age-related macular degeneration have slower progression of their condition if they eat a diet high in docosahexaenoic acid, while a diet rich in DHA and with a low glycemic index is associated with slower progression of the advanced stage of the disease, according to a study published online June 9 in the British Journal of Ophthalmology. 2009-06-10T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/242009/602684/tuna.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/242009/602684null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Topical-nepafenac-efficacy-is-suggested-by-retrosp/ArticleStandard/Article/detail/603262?contextCategoryId=46408&ref=25 A retrospective study analyzed outcomes in 18 patients who were treated for idiopathic or post-cataract surgery cystoid macular edema with nepafenac 0.1% (Nevanac, Alcon Laboratories) alone or combined with a corticosteroid. Statistically significant improvements were achieved in mean visual acuity and foveal thickness in both groups. 2009-06-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/242009/603262null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Stem-cells-may-help-heal-damaged-retinal-tissue-ac/ArticleStandard/Article/detail/599871?contextCategoryId=46408&ref=25 Stem cells taken from bone marrow show promise in healing damaged retinal tissue, according to researchers at the University of Louisville. 2009-05-26T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/222009/599871null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/AMD-and-reduced-cognitive-function-linked-accordin/ArticleStandard/Article/detail/598749?contextCategoryId=46408&ref=25 Dementia and age-related macular degeneration (AMD) could have a similar pathogenesis because of an association between AMD and reduced cognitive function in older people, according to a study. 2009-05-19T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/212009/598749null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diet-May-Protect-Against-Age-Related-Macular-Degen/ArticleNewsFeed/Article/detail/598033?contextCategoryId=46408&ref=25 Dietary intake may have an influence over the risk of developing age-related macular degeneration, according to two studies published in the May issue of the Archives of Ophthalmology, while a third study in the same issue indicates that cognitive impairment may share common risk factors with the eye condition. 2009-05-13T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/202009/598033/eyeexam_18202.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/202009/598033null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Key-Nutrients-Lower-Risk-of-Macular-Degeneration/ArticleNewsFeed/Article/detail/597339?contextCategoryId=46408&ref=25 The intake of certain key nutrients can reduce the risk of age-related macular degeneration and that risk can be correlated with a nutrient compound score devised by researchers and reported in the May issue of Ophthalmology. 2009-05-08T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/192009/597339/eyeinjury_18203.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/192009/597339null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Complement-inhibitor-POT-4-had-no-serious-adverse-/ArticleStandard/Article/detail/599638?contextCategoryId=46408&ref=25 POT-4, the first complement inhibitor to enter clinical trials, was found to be safe in 18 patients in a phase I clinical trial. No significant adverse side effects, ocular or systemic, were found at doses ranging up to 450 μg per eye and at follow-up up to 1 year. Complement inhibitors shut down the complement activation cascade that can lead to inflammation, tissue damage, and upregulation of vascular endothelial growth factor. 2009-05-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/222009/599638null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diabetic-macular-edema-intravitreal-insert-shows-p/ArticleStandard/Article/detail/599647?contextCategoryId=46408&ref=25 A 3-year, phase II study is investigating low and high doses of a fluocinolone acetonide intravitreal insert (Iluvien [formerly known as Medidur FA], Alimera Sciences) for the treatment of diabetic macular edema. Interim analysis of data from 12 months suggests the two doses may have similar efficacy; however, IOP-related adverse events have been confined to eyes in the high-dose group. 2009-05-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/222009/599647null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Investigational-integrin-antagonist-well-tolerated/ArticleStandard/Article/detail/599652?contextCategoryId=46408&ref=25 The investigational integrin antagonist JSM6427, administered intravitreally, caused no drug-related adverse events in a multicenter, phase I safety and pharmacokinetic study. The agent is being studied as a potential therapy for patients with neovascular age-related macular degeneration (AMD). It works by preventing the α-5 β-1 integrin from binding to fibronectin, thus blocking one of the pathways of AMD pathogenesis. 2009-05-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/222009/599652null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Predictive-model-created-for-AMD-according-to-rese/ArticleStandard/Article/detail/595346?contextCategoryId=46408&ref=25 A formula created by researchers at Tufts Medical Center will predict how likely it is for individuals with certain genetic profiles and lifestyle behaviors to develop advanced age-related macular degeneration (AMD). 2009-04-28T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/182009/595346null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Vitamin-supplement-phase-II-results-find-improveme/ArticleStandard/Article/detail/595238?contextCategoryId=46408&ref=25 Results were released from the second phase of the Multifocal Electroretinogram study of patients placed on supplemental vitamins, minerals, and carotenoids—a combination also known as macular health—to improve deteriorating maculas due to age-related macular degeneration. 2009-04-27T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/182009/595238null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/High-resolution-SD-OCT-offers-advantages-to-clinic/ArticleStandard/Article/detail/597240?contextCategoryId=46408&ref=25 A proprietary high-resolution spectral-domain optical coherence tomograph (Spectralis, Heidelberg Engineering) offers many advantages to clinicians, such as superior image quality, true multimodal imaging, and improved monitoring of disease progression, says one doctor. 2009-04-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/192009/597240null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/SD-OCT-provides-improvement-in-imaging-compared-wi/ArticleStandard/Article/detail/597258?contextCategoryId=46408&ref=25 Spectral-domain optical coherence tomography (SD-OCT) represents an improvement in imaging compared with time-domain OCT and, therefore, the potential for improved patient care. Proprietary technology (3D OCT 1000, Topcon Medical Systems) is easy to use and has versatile software, according to one ophthalmologist. The choice of any SD-OCT unit, however, must be based on an analysis of an individual practice's needs. 2009-04-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/192009/597258null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Spectral-domain-OCT-unit-offers-high-quality-retin/ArticleStandard/Article/detail/597236?contextCategoryId=46408&ref=25 A number of factors should be considered when choosing a spectral-domain optical coherence tomography system. Although the capabilities of many systems essentially are similar, some differences exist based on ease of image acquisition and quality, software versatility, and other factors that may make them the best choice for a specific practice's needs. Proprietary technology (RTVue-100, Optovue Inc.) has the capability to perform both retinal and anterior segment imaging, which may make it a versatile instrument for a general ophthalmology practice, according to one practitioner. 2009-04-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/192009/597236null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Sharp-Rise-in-Macular-Degeneration-Cases-Expected/ArticleNewsFeed/Article/detail/593311?contextCategoryId=46408&ref=25 Although the prevalence of age-related macular degeneration is set to significantly increase by 2050, the advent of new treatments will help to mitigate the health care burden, according to a report published in the April issue of the Archives of Ophthalmology. 2009-04-14T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/162009/593311/eye_SS36006.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/162009/593311null XML http://www.modernmedicine.com/modernmedicine/Industry+News/Favorable-safety-efficacy-seen-in-12-month-interim/ArticleStandard/Article/detail/590896?contextCategoryId=46408&ref=25 Alimera Sciences Inc., has made available the interim, 12-month safety and efficacy data from the first human pharmacokinetic study of fluocinolone acetonide intravitreal insert (Iluvien), which is currently under development for the treatment of diabetic macular edema, the company said in a prepared statement. 2009-04-01T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/142009/590896null HTML http://www.modernmedicine.com/modernmedicine/Industry+News/ThromboGenics-completes-enrollment-for-MIVI-II-DME/ArticleStandard/Article/detail/587014?contextCategoryId=46408&ref=25 ThromboGenics has completed patient enrollment for a phase II trial of microplasmin intravitreal injection for the treatment of diabetic macular edema, according to a statement issued by the company. 2009-03-18T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/112009/587014null HTML http://www.modernmedicine.com/modernmedicine/Industry+News/Roche-Genentech-reach-agreement/ArticleStandard/Article/detail/587007?contextCategoryId=46408&ref=25 Roche and Genentech announced that they have signed a merger agreement in which Roche will acquire the outstanding publicly held shares of Genentech for $95 per share, or $46.8 billion, according to statements issued by both companies. 2009-03-18T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/112009/587007null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Scientists-try-to-find-easier-way-to-detect-early-/ArticleStandard/Article/detail/587480?contextCategoryId=46408&ref=25 Beams of light are being used as a less invasive, less expensive approach to spot early stages of retinal damage from diabetic retinopathy by measuring blood flow in the back of the eye, according to scientists in California. 2009-03-16T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/122009/587480null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Developments-in-age-related-macular-degeneration-D/ArticleStandard/Article/detail/585384?contextCategoryId=46408&ref=25 Remarkable and rapid shifts have occurred in the treatment of age-related macular degeneration, and primary care physicians can play a front-line role in ensuring their patients benefit from the progress being made against what is still the leading cause of legal blindness of Americans aged 65 and older. 2009-03-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/geriatrics/102009/585384null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Perioperative-ketorolac-significantly-reduces-cyst/ArticleStandard/Article/detail/589238?contextCategoryId=46408&ref=25 A prospective, randomized, investigator-masked clinical trial randomly assigned 546 patients without risk factors for postoperative cystoid macular edema (CME) to receive postoperative treatment with a corticosteroid alone or combined with ketorolac tromethamine 0.4% (Acular LS, Allergan) in an extended perioperative/postoperative regimen. The addition of ketorolac had statistically significant benefits for reducing the incidences of CME (diagnosed clinically and by OCT) and macular thickening. 2009-03-15T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/132009/589238null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Ophthalmologists-have-unique-opportunity-to-influe/ArticleStandard/Article/detail/586046?contextCategoryId=46408&ref=25 Diabetes prevalence has doubled in the past decade, and the increases in diabetes-related eye disease poses a new challenge to eye specialists, according to an editorial in the March issue of Archives of Ophthalmology. 2009-03-10T04:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/112009/586046null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Macular-degeneration-may-have-same-biomarker-as-ki/ArticleStandard/Article/detail/585200?contextCategoryId=46408&ref=25 Cystatin C, a biomarker of kidney function, also may be associated with the incidence of age-related macular degeneration (AMD), said researchers. 2009-03-05T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/102009/585200null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Laser-burn-injuries-in-one-eye-can-affect-immune-p/ArticleStandard/Article/detail/584799?contextCategoryId=46408&ref=25 A laser burn to one retina can cause both eyes to lose immune privilege, according to scientists at Schepens Eye Research Institute. 2009-03-04T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/102009/584799null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/AMD-not-made-worse-by-cataract-surgery-according-t/ArticleStandard/Article/detail/584514?contextCategoryId=46408&ref=25 According to new research, cataract surgery does not hasten vision loss in people with age-related macular degeneration (AMD). 2009-03-03T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/102009/584514null HTML http://www.modernmedicine.com/modernmedicine/Industry+News/March-is-AMD-Awareness-Month/ArticleStandard/Article/detail/584248?contextCategoryId=46408&ref=25 March is Age-Related Macular Degeneration (AMD) Awareness Month, and the American Academy of Ophthalmology (AAO), the American Society of Retina Specialists, the Macula Society, and the Retina Society have teamed up to encourage Americans to become more aware of their risks for AMD. 2009-03-02T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/102009/584248null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diabetic-retinopathy-A-growing-concern-in-an-aging/ArticleStandard/Article/detail/580283?contextCategoryId=46408&ref=25 Diabetic retinopathy is a rising threat as the population ages and the number of diabetics aged 60 and older increases. Appropriate screening by primary care providers and geriatric specialists can ensure its early detection, while optimal management of blood glucose levels and hypertension can reduce its incidence and progression. 2009-02-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/geriatrics/062009/580283null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Charles-Bonnet-syndrome-may-explain-visual-halluci/ArticleStandard/Article/detail/582487?contextCategoryId=46408&ref=25 Complex visual hallucinations experienced by visually impaired patients are often indicative of Charles Bonnet syndrome. Individuals who experience these hallucinations usually understand that they are not real but will benefit from a doctor's explanation that they are associated with their vision loss and are unlikely to be a sign of mental illness. 2009-02-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/082009/582487null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Feature+Articles/Retina-Tool-Strategic-plans-help-retina-practice/ArticleStandard/Article/detail/579919?contextCategoryId=46408&ref=25 Amid adding partners, opening new offices, and managing unprecedented growth, Mid Atlantic Retina turned to a consulting firm (Advantage Administration Inc.) to develop a strategic plan for the ensuing years. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/579919null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Oral-fenretinide-investigated-for-dry-age-related-/ArticleStandard/Article/detail/580302?contextCategoryId=46408&ref=25 Oral fenretinide (Sirion Therapeutics) is being investigated in a phase II study as a treatment for advanced geographic atrophy associated with age-related macular degeneration. It is hypothesized that this agent may limit disease progression by preventing delivery of circulating retinol to the eye, thereby reducing the accumulation of retinol-derived metabolites that are toxic to the retinal pigment epithelium and photoreceptor cells. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580302null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Anti-vascular-endothelial-growth-factor-agent-prov/ArticleStandard/Article/detail/580304?contextCategoryId=46408&ref=25 In a small retrospective study, eyes receiving intravitreal bevacizumab (Avastin, Genentech) within 3 months of a central retinal vein occlusion showed rapid improvement in anatomic abnormalities and subsequent improvement in vision. The benefits were maintained with repeated injections after a mean follow-up of 1 year. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580304null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/25-gauge-vitrectomy-scrutinized-by-task-force/ArticleStandard/Article/detail/580298?contextCategoryId=46408&ref=25 The Micro-Surgical Safety Task Force analyzed potential complications associated with sutureless vitrectomy and disseminated guidelines to reduce the rate of endophthalmitis associated with 25-gauge vitrectomy. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580298null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Induction-maintenance-therapy-shows-promise-for-ne/ArticleStandard/Article/detail/580299?contextCategoryId=46408&ref=25 Employing a therapeutic approach consisting of pan-vascular endothelial growth factor (VEGF) blockers such as ranibizumab (Lucentis, Genentech) and/or bevacizumab (Avastin, Genentech) as an induction therapy, followed by a selective VEGF blocker such as pegaptanib (Macugen, OSI/Eyetech) as a maintenance therapy, appears to be effective in patients with neovascular age-related macular degeneration, according to the interim results of the LEVEL study. This approach may be preferred for many patients from the standpoint of systemic safety. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580299null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Vascular-endothelial-growth-factor-antagonists-wil/ArticleStandard/Article/detail/580295?contextCategoryId=46408&ref=25 Antagonists of vascular endothelial growth factor provide a benefit for choroidal neovascularization and are promising for other retinal diseases, but they represent only the beginning of a transformation in the treatment of certain eye diseases, according to one ophthalmologist. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580295null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dry-age-related-macular-degeneration-antioxidant-d/ArticleStandard/Article/detail/580306?contextCategoryId=46408&ref=25 A topical eye drop (OT-551, Othera) is being investigated to treat geographic atrophy in dry age-related macular degeneration. The treatment is an antioxidant that in vitro protects against antioxidative damage and in vivo protects against light damage. One-year data are expected to be reported in the spring. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580306null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Nonischemic-retinal-vein-occlusion-treated-with-ra/ArticleStandard/Article/detail/580435?contextCategoryId=46408&ref=25 One year follow-up results of a small study of ranibizumab (Lucentis, Genentech) in patients with nonischemic retinal vein occlusion show that all treated patients gained VA or that VA remained stable, although this improvement was accompanied by decreases in contrast sensitivity and reading ability. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/072009/580435null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diabetic-retinopathy-treated-with-micropulsed-diod/ArticleStandard/Article/detail/580297?contextCategoryId=46408&ref=25 The treatment of diabetic retinopathy seems to be managed well with the use of the diode laser. According to one expert, the micropulsed diode laser is particularly effective in treatment of this disease, offering patients a safe and painless treatment solution. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580297null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Rapamycin-safe-for-treating-diabetic-macular-edema/ArticleStandard/Article/detail/580303?contextCategoryId=46408&ref=25 A phase 1 trial of rapamycin (Sirolimus, MacuSight) indicated that the drug is safe and has biologic activity in patients with diabetic macular edema when injected intravitreally and subconjunctivally. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580303null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Microincision-vitrectomy-surgery-is-gaining-popula/ArticleStandard/Article/detail/580301?contextCategoryId=46408&ref=25 Microincision vitrectomy surgery has rapidly gained increased popularity. It is associated with many advantages, but there have been some reports of disadvantages such as a significantly higher incidence of endophthalmitis postoperatively, though more recent reports do not substantiate this conclusion. Advances in the technology likely will facilitate safer and more efficient vitrectomy. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580301null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Spectral-domain-optical-coherence-tomography-has-p/ArticleStandard/Article/detail/580300?contextCategoryId=46408&ref=25 Spectral-domain optical coherence tomography is becoming an invaluable diagnostic tool and greatly helps ophthalmologists better manage their patients' conditions, according to one expert. This improved management of conditions, he said, can be realized not only in the medical arena but also in the surgical arena as well. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580300null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Vitrectomy-cutter-offers-high-speed-cutting-contro/ArticleStandard/Article/detail/580296?contextCategoryId=46408&ref=25 A new surgical platform (Constellation Vision System, Alcon Laboratories) incorporates advanced design features for improved surgical efficiency and safety. Vitrectomy probes (Ultravit, Alcon) facilitate high-speed cutting and control of the duty cycle. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580296null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Age-related-macular-degeneration-complement-blocke/ArticleStandard/Article/detail/580305?contextCategoryId=46408&ref=25 JPE1375 (Jerini Ophthalmic), a peptidomimetic inhibitor of the complement factor 5a receptor, blocks the mechanism that draws inflammatory cells into the disease process of age-related macular degeneration. When blocked, the numbers of neutrophils and macrophages decrease substantially and in turn the choroidal neovascularization also decreases. 2009-02-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/062009/580305null XML http://www.modernmedicine.com/modernmedicine/Industry+News/Topcon-granted-FDA-clearance-for-OCT-measurement-s/ArticleStandard/Article/detail/576660?contextCategoryId=46408&ref=25 Topcon Medical Systems has received FDA clearance for its enhanced 3D optical coherence tomography measurement software (OCT-1000 TrueMap) as an addition to its previously cleared OCT system (3D OCT-1000), according to a prepared statement. 2009-01-20T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/042009/576660null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Patients-with-wet-age-related-macular-degeneration/ArticleStandard/Article/detail/577631?contextCategoryId=46408&ref=25 Ophthalmologists in Canada are hoping that an outbreak of ocular inflammation in patients being treated with bevacizumab (Avastin, Genentech) will not cause stricter regulations against its off-label intravitreal use or deter doctors from using it to treat wet age-related macular degeneration. All of the confirmed cases were linked to a specific lot of the drug that was distributed throughout Canada and other parts of the world. Health Canada currently is working with an independent laboratory to complete tests to determine the cause of the outbreak. 2009-01-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/052009/577631null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Protein-discovery-may-lead-to-prevention-of-blindn/ArticleStandard/Article/detail/574998?contextCategoryId=46408&ref=25 A protein has been identified that appears to prolong the lives of retinal cells in both healthy and diseased eyes, according to researchers. 2009-01-12T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/032009/574998null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Diabetes-eye-disease-expected-to-increase-accordin/ArticleStandard/Article/detail/573696?contextCategoryId=46408&ref=25 The number of Americans with major eye diseases is expected to increase drastically over the next several decades as more people are diagnosed with diabetes, according to a new study. 2009-01-05T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/022009/573696null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Retinal-detachment-highly-treatable-due-to-latest-/ArticleStandard/Article/detail/573154?contextCategoryId=46408&ref=25 Although retinal detachments puts an individual at risk for vision loss or blindness, a new study published in the New England Journal of Medicine showed that a high probability of reattachment and visual improvement is possible by using one of the three currently available surgical techniques. 2008-12-24T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/522008/573154null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Photodynamic-Therapy-Helps-to-Treat-Chorioretinopa/ArticleNewsFeed/Article/detail/572622?contextCategoryId=46408&ref=25 Photodynamic therapy can resolve localized serous retinal detachment of the macula and lead to visual improvement in patients with chronic idiopathic central serous chorioretinopathy, according to research published in the December issue of Lasers in Surgery and Medicine. 2008-12-19T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/512008/572622/SS36001.jpg http://www.modernmedicine.com/modernmedicine/data/articlenewsfeed/modernmedicine/512008/572622null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Retina-2008-The-year-of-watchful-waiting/ArticleStandard/Article/detail/572058?contextCategoryId=46408&ref=25 Retinal specialists seemed to hold their collective breaths in 2008 in anticipation of the results of a number of ongoing trials of drugs for various retinal pathologies. Medical retina and the anti-vascular endothelial growth factor therapies were center stage again this year. Some of the highlights include bevacizumab (Avastin, Genentech) for retinopathy of prematurity, sustained-release ciliary neurotropic factor for dry age-related macular degeneration, anti-complement drugs, and the results of the Diabetic Retinopathy Clinical Research study. 2008-12-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/512008/572058null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Retinal-oxygen-levels-measurement-allowed-by-hyper/ArticleStandard/Article/detail/568129?contextCategoryId=46408&ref=25 A new hyperspectral camera can measure the oxygen level of the retinal tissues non-invasively. This may allow detection of retinal changes in patients with diabetes, and other retinal vascular diseases, before structural changes in the capillaries occur. 2008-12-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/482008/568129null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dr-Williams-named-American-Society-of-Retina-Speci/ArticleStandard/Article/detail/568119?contextCategoryId=46408&ref=25 David F. Williams, MD, MBA, has been named president of the American Society of Retina Specialists (ASRS). 2008-12-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/482008/568119null XML http://www.modernmedicine.com/modernmedicine/Industry+News/Age-related-macular-degeneration-awareness-raised-/ArticleStandard/Article/detail/568819?contextCategoryId=46408&ref=25 For seniors with age-related macular degeneration (AMD), the answer to the question "Do you see what I see?" is always no. 2008-12-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/492008/568819null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Ophthalmologists-lauded-at-the-American-Society-of/ArticleStandard/Article/detail/568118?contextCategoryId=46408&ref=25 Neil M. Bressler, MD, Susan B. Bressler, MD, Alexander J. "Sandy" Brucker, MD, and Stanley Chang, MD, were honored for their work in the subspecialty of retina Oct. 12 at the annual meeting of the American Society of Retina Specialists (ASRS). 2008-12-01T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/482008/568118null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Electromagnetic-deformable-mirror-assists-in-retin/ArticleStandard/Article/detail/566353?contextCategoryId=46408&ref=25 The novel technology found at the heart of an adaptive optics flood illumination fundus camera (AOFIFC, INOVEO)—an electromagnetic deformable mirror (Mirao 52-e, Imagine Eyes)—is designed to facilitate the acquisition of even higher resolution images than those captured by optical coherence tomography systems. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566353null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Neovascular-age-related-macular-degeneration-patie/ArticleStandard/Article/detail/566347?contextCategoryId=46408&ref=25 Visual acuity gains occurring in a 12-week, fixed-dose period were maintained throughout the 52-week trial of a novel agent (VEGF Trap-Eye, Regeneron Pharmaceuticals) for neovascular age-related macular degeneration. During the 9-month, as-needed dosing phase, the mean number of injections for all patients was two, and gains in visual acuity of up to nine letters were reported. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566347null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Age-related-macular-degeneration-and-diabetic-reti/ArticleStandard/Article/detail/566344?contextCategoryId=46408&ref=25 Drug development for retinal disease is particularly challenging because traditional routes of drug delivery often are unable to achieve desired therapeutic levels, and the disease process often involves multiple complex pathways. An unmet medical need still exists—particularly for the two most prevalent diseases, age-related macular degeneration and diabetic retinopathy—but several phase III trials show promise. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566344null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Posterior-vitreous-detachment-inducement-may-be-ac/ArticleStandard/Article/detail/566349?contextCategoryId=46408&ref=25 In a dose-ranging phase IIb study, microplasmin 125 micrograms (ThromboGenics) was safe and demonstrated significant efficacy compared with placebo for inducing posterior vitreous detachment in eyes with macular holes or macular edema related to vitreomacular traction. Pivotal phase III trials are being planned. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566349null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Intravitreal-ranibizumab-therapy-safe-well-tolerat/ArticleStandard/Article/detail/566351?contextCategoryId=46408&ref=25 1-year results from the HORIZON open-label extension study of ranibizumab (Lucentis, Genentech) for the treatment of exudative age-related macular degeneration show that treatment beyond 2 years relatively is safe and well tolerated, but previously treated patients who received ranibizumab monthly for 2 years may be susceptible to loss of vision with less-frequent dosing during the third year of treatment. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566351null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Inherited-lebers-congenital-amaurosis-gene-therapy/ArticleStandard/Article/detail/566350?contextCategoryId=46408&ref=25 A novel gene therapy approach for the treatment of a type of inherited retinal disease appears to be safe and effective in initial trials. Results offer hope for the treatment of a gamut of eye diseases that once were thought to be untreatable, according to one researcher. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566350null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diabetic-macular-edema-intravitreal-insert-treatme/ArticleStandard/Article/detail/566339?contextCategoryId=46408&ref=25 A new intravitreal insert (Iluvien, Alimera Sciences) currently in clinical trials manages a slow, long-term release of corticosteroid into the vitreous chamber. Preliminary results show the device to be very promising and possibly more favorable than other similar devices used for the treatment of diabetic macular edema. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566339null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Prosthesis-prototype-eyed-for-testing-in-volunteer/ArticleStandard/Article/detail/566338?contextCategoryId=46408&ref=25 A collaborative effort to design an intracortical visual prosthesis has progressed to the point that tests of a prototype in a human volunteer are being planned. The results of psychophysical testing in normal volunteers indicate that the prosthesis could provide sufficient visual functionality to enable users to perform useful visual tasks. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566338null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Exudative-age-related-macular-degeneration-update-/ArticleStandard/Article/detail/566346?contextCategoryId=46408&ref=25 When data were analyzed from 25 patients who reached the 18-month visit in a phase II trial evaluating epiretinal brachytherapy (EpiRad90 Ophthalmic System, NeoVista) with bevacizumab (Avastin, Genentech), they demonstrated that the novel combination was associated with a significant gain in vision, an acceptable safety profile, and with minimal need for additional anti-VEGF treatment beyond an initial two injections. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566346null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/A-19-year-old-female-has-transient-black-spots-hea/ArticleStandard/Article/detail/566081?contextCategoryId=46408&ref=25 A 19-year-old Latin female presented to the Bascom Palmer emergency room complaining of transient black spots in the right eye. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566081null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Diabetic-macular-edema-can-be-objectively-detected/ArticleStandard/Article/detail/566352?contextCategoryId=46408&ref=25 Both subjective and objective evaluation of diabetic macular edema (DME) can produce good results. In a recent study, the initial results of objective evaluation with retinal imaging technology (Heidelberg Retina Tomograph Retina Module, Heidelberg Engineering) showed good sensitivity and moderate specificity, whereas subjective evaluation by two expert assessors produced high sensitivity and specificity. Nevertheless, with optimization, the results of the two forms of evaluation became more evenly matched, suggesting that the retinal imaging technology can aid clinicians in detecting DME. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566352null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/End-stage-age-related-macular-degeneration-investi/ArticleStandard/Article/detail/566345?contextCategoryId=46408&ref=25 A prismatic IOL (P-Flex, Rayner) is giving hope to patients with advanced age-related macular degeneration because of its novel design. A Fresnel prism in the IOL reflects images onto healthy retinas in patients with small macular lesions. No scotoma or diplopia has resulted from implantation of this IOL in two patients. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566345null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Choroidal-neovascularization-future-treatment-may-/ArticleStandard/Article/detail/566348?contextCategoryId=46408&ref=25 Adjuvant use of bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) with ranibizumab (Lucentis, Genentech) reduced the reduced the number of ranibizumab injections needed to control choroidal neovascularization secondary to age-related macular degeneration. Use of the two drugs together resulted in better visual acuity outcomes than those achieved with ranibizumab alone. 2008-11-15T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/566348null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Dietary-supplement-combats-oxidative-stress-associ/ArticleStandard/Article/detail/565096?contextCategoryId=46408&ref=25 The launch of a specialized dietary supplement (DiaVis, ScienceBased Health) to support the visual and overall health of those with diabetes was announced at the American Academy of Ophthalmology meeting. 2008-11-10T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/565096null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Distinct-patterns-of-diabetic-maculopathy-seen-on-/ArticleStandard/Article/detail/565080?contextCategoryId=46408&ref=25 Optical coherence tomography (OCT) is valuable in managing diabetic macular edema (DME), more so than fluorescein angiography, in which the degree of leakage is not correlated with visual acuity and outcomes, according to Peter Kaiser, MD. In addition, angiography does not show vitreoretinal abnormalities that may require a different treatment. 2008-11-10T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/565080null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Possible-future-adjunctive-role-for-anti-VEGF-drug/ArticleStandard/Article/detail/565083?contextCategoryId=46408&ref=25 Anti-vascular endothelial growth factors (VEGF) drugs may have a role in the treatment of diabetic maculopathy, according to Robert Avery, MD, of Santa Barbara, CA. 2008-11-10T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/565083null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Laser-photocoagulation-still-standard-of-care-for-/ArticleStandard/Article/detail/565081?contextCategoryId=46408&ref=25 The Early Treatment Diabetic Retinopathy Study (EDTRS) laser is still the standard of care of diabetic maculopathy. There is enthusiastic support for the potential of pharmaceutical therapy, using anti-vascular endothelial growth factor agents, however, the laser remains the gold standard, said Francesco Bandello, MD, of the University of Udine, Udine, Italy. 2008-11-10T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/565081null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/AAO-Use-of-VEGF-inhibitors-studied-in-different-re/ArticleStandard/Article/detail/564733?contextCategoryId=46408&ref=25 Anti-VEGF therapy has met with widespread acceptance in the ophthalmic community, and a recent poll of retinal specialists suggest it is being used off-label, as well as formally studied in clinical trials, for conditions other than age-related macular degeneration, including proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). Anti-VEGF therapy, however, has yet to be studied in a randomized controlled clinical trial of diabetic retinopathy, according to Francesco Boscia, MD, professor, Department of Ophthalmology and Otolaryngology, Bari, Italy. 2008-11-09T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/564733null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/Future-directions-in-development-of-VEGF-antagonis/ArticleStandard/Article/detail/564730?contextCategoryId=46408&ref=25 Ranibizumab (Lucentis, Genentech) has revolutionized the treatment of age-related macular degeneration, but the impressive results from clinical trials lead to new questions. Is long-term suppression of vascular endothelial growth factor (VEGF) in the eye safe? Do other members of the VEGF gene family contribute to retinal vascular diseases? Are other cytokines or growth factors involved in disease pathogenesis? Are there safe and effective delivery methods other than monthly injections? 2008-11-09T05:00:00Z http://www.modernmedicine.com/modernmedicine/data/articlestandard/ophthalmologytimes/462008/564730null HTML